[Endothelin and essential hypertension].
Kataoka
Kei-ichiro
K
Department of Physiological Chemistry and Metabolism, Graduate School of Medicine, The University of Tokyo.
Kurihara
Yukiko
Y
Kurihara
Hiroki
H
D000818:Animals; D000959:Antihypertensive Agents / Q000627:therapeutic use; D001794:Blood Pressure; D015195:Drug Design; D065128:Endothelin Receptor Antagonists; D019332:Endothelin-1 / Q000037:antagonists & inhibitors / Q000235:genetics / Q000502:physiology*; D006801:Humans; D006973:Hypertension / Q000188:drug therapy / Q000209:etiology*; D051379:Mice; D018345:Mice, Knockout; D009119:Muscle Contraction; D009131:Muscle, Smooth, Vascular; D010456:Peptides, Cyclic / Q000627:therapeutic use; D011743:Pyrimidines / Q000627:therapeutic use; D017466:Receptors, Endothelin / Q000502:physiology; D013449:Sulfonamides / Q000627:therapeutic use; D000096926:Benzenesulfonamides
D000959:Antihypertensive Agents; D065128:Endothelin Receptor Antagonists; D019332:Endothelin-1; D010456:Peptides, Cyclic; D011743:Pyrimidines; D017466:Receptors, Endothelin; D013449:Sulfonamides; C083751:Ro 46-2005; D000096926:Benzenesulfonamides; C072247:cyclo(Trp-Asp-Pro-Val-Leu)